Clinical Trial Search

Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 1; 2; 0; 1 participants

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 6; 40; 9; 7 milligrams (mg)

Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…

Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants

Primary: Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only — 4.7; 5.2; 10; 0 percentage of participants

Primary: Overall Response Rate (Confirmed) — 1; 1 Participants

Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting…

Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants

Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants

Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg

Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs

Primary: Overall Survival — 13.43; 7.62 months

Primary: Objective Response Rate Measured by RECIST Version 1.1 — 1; 19; 32; 76 Participants

Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…

Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)

Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants

Primary: Phase Ia: Number of Patients With DLTs Observed in the First Cycle — 0; 0; 0; 0 Participants

Primary: Safety and Tolerability Measured by Assessing Serious Adverse Events (SAEs)and Adverse Events (AEs) — 1; 3; 2; 2 Participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 participants

Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants

Primary: Retention Rate — 38; 3 Participants

Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants

Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants

Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants

Primary: Proportion of Evaluable Participants Who Experience Clinical Benefit (Disease Control Rate = Complete Response (CR)+Partial Response (PR)+Stable Disease x16 Weeks)…

Primary: Part A: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events…

Primary: Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement) — 0 participants